SOLLAZZO, DARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.627
EU - Europa 1.015
AS - Asia 651
AF - Africa 69
OC - Oceania 6
SA - Sud America 3
Totale 3.371
Nazione #
US - Stati Uniti d'America 1.616
GB - Regno Unito 280
SE - Svezia 209
VN - Vietnam 206
CN - Cina 199
IT - Italia 154
DE - Germania 136
SG - Singapore 126
IN - India 72
IE - Irlanda 57
FR - Francia 36
RU - Federazione Russa 36
EE - Estonia 23
TG - Togo 23
BG - Bulgaria 21
ZA - Sudafrica 21
JO - Giordania 19
UA - Ucraina 17
BE - Belgio 14
CH - Svizzera 12
CA - Canada 11
CI - Costa d'Avorio 11
NG - Nigeria 11
FI - Finlandia 10
IR - Iran 8
MY - Malesia 8
AU - Australia 5
JP - Giappone 3
BR - Brasile 2
EG - Egitto 2
ID - Indonesia 2
LB - Libano 2
NO - Norvegia 2
TR - Turchia 2
AT - Austria 1
BD - Bangladesh 1
CZ - Repubblica Ceca 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
LT - Lituania 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
VE - Venezuela 1
Totale 3.371
Città #
Southend 250
Chandler 224
Fairfield 194
Ashburn 116
Dong Ket 109
Singapore 104
Woodbridge 99
Houston 91
Seattle 88
Cambridge 82
Wilmington 70
Ann Arbor 63
Princeton 61
Dublin 57
Santa Clara 48
Bologna 41
Boardman 33
Redmond 26
Bremen 25
Westminster 25
Beijing 23
Lomé 23
Nanjing 23
Sofia 21
Jinan 20
Amman 19
Padova 19
Berlin 18
Turin 17
Brussels 14
Milan 12
Saint Petersburg 12
Shenyang 12
Abeokuta 11
Abidjan 11
Medford 11
New York 11
Changsha 10
Falls Church 10
Helsinki 10
Hyderabad 10
Bern 9
Florence 9
Nanchang 9
San Diego 9
Kuala Lumpur 7
Redwood City 7
Fremont 6
Hebei 6
Los Angeles 6
Zhengzhou 6
Hangzhou 5
Tianjin 5
Winnipeg 5
Guangzhou 4
Hefei 4
Jiaxing 4
Leawood 4
Taiyuan 4
Xi'an 4
Zanjan 4
Andover 3
Caprino Veronese 3
Chicago 3
Des Moines 3
Gloucester 3
Kuban 3
Lanzhou 3
Mountain View 3
Munich 3
Pune 3
Rome 3
Shanghai 3
Tokyo 3
Toronto 3
Wenzhou 3
Amherst Junction 2
Baltimore 2
Boston 2
Bühl 2
Cairo 2
Castenaso 2
Frankfurt am Main 2
Handan 2
Henderson 2
Jakarta 2
Lanciano 2
North York 2
Olalla 2
Paris 2
Parma 2
Pavia 2
Phoenix 2
Plauen 2
Romainville 2
San Francisco 2
San Jose 2
San Mateo 2
Shijiazhuang 2
Suzhou 2
Totale 2.333
Nome #
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 200
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 174
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 147
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 145
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 143
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 143
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 140
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 137
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 133
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 128
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 123
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 118
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 117
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 115
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 111
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 108
null 107
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 105
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 101
null 98
null 96
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 93
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 91
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 91
CD 133+ stem cells for the treatment of end stage liver disease. 87
The CD47 pathway is deregulated in human immune thrombocytopenia 86
CD133+ stem cells for the treatment of end-stage liver disease 74
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 66
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 54
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 46
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 40
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 40
Totale 3.457
Categoria #
all - tutte 8.985
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.985


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020513 0 0 0 0 0 78 89 101 105 61 39 40
2020/2021510 75 21 7 6 22 15 11 16 47 28 20 242
2021/2022663 25 45 28 78 60 20 12 36 24 76 141 118
2022/2023780 82 116 47 107 50 61 18 48 130 35 63 23
2023/2024189 19 29 11 35 12 41 4 13 5 5 8 7
2024/2025315 39 70 52 55 78 21 0 0 0 0 0 0
Totale 3.457